Powder: -20°C for 3 years | In solvent: -80°C for 1 year
VU534 is a NAPE-PLD agonist with an EC50 of 0.30 μM.VU534 is a dual inhibitor of FAAH and sEH, with an IC50 of 1.2 μM for sEH.VU534 is used in diseases related to cardiometabolism.
パッケージサイズ | 在庫状況 | 単価(税別) | |||
---|---|---|---|---|---|
サンプルについてお問い合わせ | |||||
1 mg | 在庫あり | ¥ 8,500 | |||
5 mg | 在庫あり | ¥ 19,500 | |||
10 mg | 在庫あり | ¥ 32,000 | |||
25 mg | 在庫あり | ¥ 54,000 | |||
50 mg | 在庫あり | ¥ 81,000 | |||
100 mg | 在庫あり | ¥ 122,500 |
説明 | VU534 is a NAPE-PLD agonist with an EC50 of 0.30 μM.VU534 is a dual inhibitor of FAAH and sEH, with an IC50 of 1.2 μM for sEH.VU534 is used in diseases related to cardiometabolism. |
ターゲット&IC50 | sEH:1.2 μM, NAPE-PLD:0.30 μM(EC50), FAAH:1.2 μM |
In vitro |
VU534 (30 μM; 24 h) is less cytotoxic to HepG2 and Raw264.7 cell lines.[1] VU534 (3~30 μM; 1 h) can increase NAPE-PLD activity in Raw264.7 cells.[1] VU534 (1 h) can increase NAPE-PLD activity in HepG2 cells with an EC50 value of 1.5 μM.[1] VU534 (5 μM, 1 h) increased NAPE-PLD activity 1.5-fold but did not reverse NAPE-PLD activity inhibited by LEI–401.[1] VU534 (10 μM; 6 h) significantly enhances efferocytosis of bone marrow-derived macrophages but cannot exert this effect when Napepld is knocked out.[1] |
分子量 | 447.55 |
分子式 | C21H22FN3O3S2 |
CAS No. | 923509-20-0 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 13.43 mg/mL (30 mM), Sonication is recommended.
You can also refer to dose conversion for different animals. 詳細
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
VU534 923509-20-0 Metabolism Neuroscience FAAH Phospholipase Epoxide Hydrolase VU-534 VU 534 Inhibitor inhibitor inhibit